DelMar’s cancer treatment show clinical activity against a range of cancers

DelMar Pharmaceuticals said Tuesday that 17 of the first 20 enrolled patients have received at least their first assessment, and nine have been assessed as having achieved a complete response (CR) (9/17, or 53%), seven have been assessed with stable disease (SD), (7/17, or 41%), while nine has been assessed as disease progression (PD) (1/17, or 6%).

Read more

Three companies to evaluate the combination of Bayer’s kinase inhibitor Stivarga and BMS’s Opdivo

Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1

Read more

Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors

Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, today announced a global license agreement for Inflection’s first-in-class PIM/PI3K/mTOR inhibitors.

Read more